Abstract
Data support that hypertension (HTN) is prevalent among human immunodeficiency virus (HIV) patients contributing to increased risk of cardiovascular disease. Immunodeficiency and prolonged antiretroviral treatment along with common risk factors including older age, male gender, and high body mass index might conduce to greater incidence of HTN. The purpose of this review was to summarize recent evidence of the increased cardiovascular risk in these patents linking HIV infection to HTN.
MeSH terms
-
Anti-HIV Agents / adverse effects
-
Antihypertensive Agents / adverse effects
-
Blood Pressure* / drug effects
-
Drug Interactions
-
HIV Infections / diagnosis
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology*
-
HIV Infections / virology
-
Healthy Lifestyle
-
Humans
-
Hypertension / diagnosis
-
Hypertension / epidemiology*
-
Hypertension / physiopathology
-
Hypertension / therapy
-
Incidence
-
Polypharmacy
-
Prevalence
-
Prognosis
-
Risk Assessment
-
Risk Factors
-
Risk Reduction Behavior
Substances
-
Anti-HIV Agents
-
Antihypertensive Agents